Business
Moleculin Reports Third Quarter 2024 Financial Results And Provides Corporate Update
(MENAFN - PR Newswire) - On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in ...
By: menafn
- Nov 11 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS